Safety, Tolerability, and Pharmacodynamic Effect Study of PUR118
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to establish single and multiple dose safety in healthy subjects and subjects with mild chronic pulmonary obstructive disease (COPD). In addition, the study will evaluate preliminary proof of concept endpoints in COPD subjects such as biomarkers in sputum and mucociliary clearance.
| Condition | Intervention | Phase |
|---|---|---|
|
Chronic Obstructive Pulmonary Disease |
Drug: PUR118 |
Phase 1 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Pharmacodynamics Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Four-Part Study to Evaluate the Safety, Tolerability and Pharmacodynamic Effects of PUR118 and Placebo in Normal Healthy Volunteers and Subjects With COPD |
- Safety and tolerability assessed by changes in clinical signs and symptoms, clinical safety laboratory tests, vital signs, ECG, spirometry, oxygen saturation, telemetry and adverse events [ Time Frame: 2 weeks ] [ Designated as safety issue: Yes ]
- Assessment of biomarkers of inflammation and COPD in induced sputum in mild COPD subjects after short multi-dosing with PUR118 compared to baseline [ Time Frame: 2 days ] [ Designated as safety issue: No ]
- Assessment of changes in mucociliary clearance after treatment with PUR118 in mild COPD subjects compared to baseline [ Time Frame: single dose ] [ Designated as safety issue: No ]
| Enrollment: | 90 |
| Study Start Date: | February 2011 |
| Study Completion Date: | June 2012 |
| Primary Completion Date: | June 2012 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: PUR118 |
Drug: PUR118
inhaled
|
Detailed Description:
The proposed initial trial in healthy subjects and subjects with mild COPD will establish the tolerability of PUR118 in these subjects over single and short multi-day dosing periods. The study will also provide preliminary data regarding PUR118's potential impact on biomarkers in COPD. Finally, this trial will assess PUR118's effect on mucociliary clearance. This is a four part study enrolling healthy volunteers in a single ascending dose design (SAD; Part I), followed by multiple ascending dose design (MAD; Part II). Contingent on demonstration of safety in a healthy subject population, the study will enroll mild COPD subjects for a short multi-dose design (Part III) incorporating safety and pharmacodynamic endpoints. Lastly Part IV of the trial will assess the effect of PUR118 on mucociliary clearance in mild COPD subjects.
Eligibility| Ages Eligible for Study: | 18 Years to 70 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Main Inclusion Criteria Parts I & II
- Healthy males or non pregnant, non lactating healthy females;
- Age 18-65 years of age;
- Must be willing and able to communicate in English and participate in the whole study;
- Must provide written informed consent.
Main Exclusion Criteria Parts I & II
- Current smokers and those who have smoked within the last 12 months;
- Females of child bearing age not willing to use an acceptable form of contraception;
- Presence or history of allergy requiring treatment;
- Serious adverse reaction or hypersensitivity to any drug;
Main Inclusion Criteria: Parts III and IV
- Males or non pregnant, non lactating females;
- Age 45-70 years;
- Current (Part III only) or ex-smokers who at least a 15 pack-year smoking history. For Part IV, subjects must be non-smokers for at least 3 months;
- Medically stable, with no evidence of uncontrolled co-existing conditions at screening;
- Must not be taking any inhaled or oral corticosteroids;
- FEV1/FVC ratio <70% and FEV1 60 - 80% (or >/= 60% for Part IV only) of predicted following administration of a bronchodilator;
- Patients must have a medical history of COPD confirmed by their General Practitioner (GP) or treating hospital physician or must have a chest x-ray (CXR) which is normal or consistent with mild COPD and excludes other clinically significant respiratory abnormalities;
- Must be willing and able to communicate in English and participate in the whole study;
- Must provide written informed consent.
Main Exclusion Criteria: Parts III and IV
- Must agree to use an adequate method of contraception;
- Upper respiratory tract infection within 30 days of the first study day, or lower respiratory tract infection within the last 60 days;
- Patients taking medication that may affect the respiratory tract within 14 days of the first study day other than their usual COPD medication;
- No active exacerbations requiring antibiotics or steroids within 60 days of dosing.
Contacts and Locations More Information
No publications provided
| Responsible Party: | Pulmatrix Inc. |
| ClinicalTrials.gov Identifier: | NCT01333904 History of Changes |
| Other Study ID Numbers: | 601-0004 |
| Study First Received: | April 7, 2011 |
| Last Updated: | September 6, 2012 |
| Health Authority: | United Kingdom: Medicines and Healthcare Products Regulatory Agency |
Additional relevant MeSH terms:
|
Lung Diseases Respiration Disorders Pulmonary Disease, Chronic Obstructive Lung Diseases, Obstructive Respiratory Tract Diseases |
ClinicalTrials.gov processed this record on May 21, 2013